Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Ophthalmology
|
| gptkbp:affects |
optic nerve
|
| gptkbp:can_be_asymptomatic_in |
early stages
|
| gptkbp:can_detect |
visual field tests
optical coherence tomography tonometry |
| gptkbp:can_lead_to |
blindness
|
| gptkbp:cause |
vision loss
irreversible blindness |
| gptkbp:diagnosis |
eye examination
|
| gptkbp:has_a_focus_on |
patient education
public health initiatives clinical research |
| https://www.w3.org/2000/01/rdf-schema#label |
open-angle glaucoma
|
| gptkbp:is_a_subject_of |
gptkb:guidelines
awareness campaigns treatment protocols screening recommendations |
| gptkbp:is_associated_with |
inflammation
family history visual impairment retinal nerve fiber layer thinning trabecular meshwork dysfunction |
| gptkbp:is_characterized_by |
increased intraocular pressure
|
| gptkbp:is_common_in |
older adults
|
| gptkbp:is_influenced_by |
gptkb:diabetes
ethnicity high blood pressure myopia |
| gptkbp:is_managed_by |
gptkb:exercise
stress reduction lifestyle changes dietary modifications |
| gptkbp:is_monitored_by |
regular eye exams
|
| gptkbp:is_often_seen_in |
angle-closure glaucoma
|
| gptkbp:is_studied_in |
ophthalmology
|
| gptkbp:requires |
lifetime management
|
| gptkbp:scientific_classification |
gptkb:neurodegenerative_diseases
eye diseases primary open-angle glaucoma secondary open-angle glaucoma |
| gptkbp:symptoms |
peripheral vision loss
tunnel vision |
| gptkbp:treatment |
gptkb:surgery
medications laser therapy beta-blockers prostaglandin analogs carbonic anhydrase inhibitors Rho kinase inhibitors alpha agonists |
| gptkbp:type_of |
chronic glaucoma
|
| gptkbp:bfsParent |
gptkb:Vyzulta
|
| gptkbp:bfsLayer |
7
|